Und dann auf "Zum Home-Bildschirm [+]".
Stöbern
genialokal zum Startbildschirm hinzufügen
Installieren Sie die genialokal App auf Ihrem Startbildschirm für einen schnellen Zugriff und eine komfortable Nutzung.
Installieren Sie die genialokal App auf Ihrem Startbildschirm für einen schnellen Zugriff und eine komfortable Nutzung.
Ihr gewünschter Artikel ist in 0 Buchhandlungen vorrätig - wählen Sie hier eine Buchhandlung in Ihrer Nähe aus:
Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.
1. General Introduction of Cancers responding to FDA-approved anti-HER2 antibodies (Trastuzumab)1B. Antibody Induction of Anticancer Immunity 2. Sensitization of Trastuzumab Response by the Combination with Pentuzumab 3. Sensitization by Lapatinib of Trastuzumab Resistance 4. Sensitization by Ganetespib (HSP90 inhibitor) of Trastuzumab Resistance 5. Sensitization by Paclitaxel of Trastuzumab Resistance 6. Sensitization by Celecoxib of Trastuzumab Resistance 7. Sensitization by Emantasine (T-DM1) of Trastuzumab Resistance 8. Sensitization by Anti-apoptotic Inhibitors of Trastuzumab Resistance 9. Sensitization by Kinase Inhibitors of Trastuzumab Resistance 10. Sensitization by Vinorelbine of Trastuzumab Resistance 11. Sensitization by Fulvestrant of Trastuzumab Resistance 12. Sensitization by IFF-1 Inhibitors of Trastuzumab Resistance 13. Sensitization by Liposomal Doxorubicin of Trastuzumab Resistance 14. Sensitization by Combination of Immunotherapy and Trastuzumab 15. Sensitization by Radiotherapy of Trastuzumab Resistance 16. Sensitization by Chemotherapy of Trastuzumab Resistance 17. New Development of Targeted Anti-HER-2 Antibodies
